On July 4, according to the Hainan Lecheng Pilot Zone Administration, Evusheld, the only neutralizing antibody drug in the world that can be used for pre-exposure prophylaxis against COVID-19, successfully passed special import approval in the Hainan Boao Lecheng International Me

Source: [Health Times]

( Health Times Zhou Xinyu) On July 4, according to the Hainan Lecheng Pioneer District Administration, the world’s only neutralizing antibody drug Evusheld ( Enshide ), successfully passed the special import approval in Hainan Boao Lecheng International Medical Tourism Pilot Zone, and is suitable for pre-exposure prophylaxis of the new coronavirus in adults and adolescents (age ≥12 years old and weight ≥40 kg).

Evusheld, a neutralizing antibody drug used for pre-exposure prophylaxis against COVID-19. Lecheng Pioneer District Administration released the picture

According to the information provided by the relevant person in charge of Ruijin Hainan Hospital, the hospital where it was launched, to the Health Times, Enshide has currently obtained Emergency Use Authorization (EUA) in the United States, and has been approved in the European Union and UK approved for pre-exposure prophylaxis against COVID-19.

Ensida consists of two fully human long-acting monoclonal antibodies tisagvirumab and cigvirumab. As long-acting neutralizing antibodies against the new coronavirus, it is preferentially suitable for people with immune function. People who are damaged or have low immunity, including patients with malignant hematological tumors or other tumors who are receiving chemotherapy, patients who are taking drugs after organ transplantation, dialysis patients, and patients with diseases such as multiple sclerosis and rheumatoid arthritis who are taking immunosuppressive drugs. .

html On June 8, AstraZeneca announced positive results from the TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly known as AZD7442) for the early outpatient treatment of mild to moderate COVID-19, published in "The Lancet Respiratory Medicine" magazine. The trial results showed that a single dose of Evusheld reduced the risk of developing severe COVID-19 or death by 50% in non-hospitalized patients with mild to moderate COVID-19 compared with placebo. Among patients treated within 3 days of symptom onset, the drug reduced the risk by 88%.

In addition, the first in vivo trial data from the University of Washington showed that Enxide reduced the viral load in the lungs of all tested Omicron (Omicron) mutant sublines.

html On July 6, the chief physician of the Department of Infectious Diseases at Beijing’s No. 1 and 3A Hospital told Health Times that the difference between this drug and the vaccine is that the vaccine is active immunity, allowing your own immune system to produce antibodies, while Enshide directly injects antibodies. It belongs to passive immunity , and the protective effect is expected to last for 6 months.

According to data, vaccination can reduce the risk of new coronavirus infection, but people with low immune function or other reasons who cannot be vaccinated are difficult to be protected. Monoclonal antibodies can provide rapid and effective protection for the human body. Some antibody drugs have been approved or emergency authorized for post-exposure prevention of COVID-19, or for the treatment of mild to moderate patients. ①

"For those who can be vaccinated, vaccination is of course the first choice. This drug is suitable for people who cannot be vaccinated or who are not expected to effectively produce antibodies after vaccination, such as people with immunosuppression and people who use immunosuppressive drugs after organ transplantation. People. This drug is suitable for different people than the vaccine, and it should be a supplement to the vaccine," said the above-mentioned infectious disease doctor.

According to data from the National Health Commission on July 6, as of July 5, 2022, 31 provinces (autonomous regions, municipalities directly under the Central Government) and the Xinjiang Production and Construction Corps have reported a total of 33,405,158,000 doses of the new coronavirus vaccine. Second-rate. The above-mentioned infectious disease doctor said that the vaccination rate in our country is already very high, but there are still some people who cannot be vaccinated, or people with low immunity, even if they are vaccinated, they cannot produce enough antibodies. This drug can give These groups provide protection.

Reference:

①astrazeneca Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in Evusheld group https://www.astrazeneca.com/media-centre/press -releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html#!

②NEJM Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2116620

This article is from [Health Times] and represents only the author’s opinion. The National Party Media Information Public Platform provides information release and dissemination services.

ID:jrtt